[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.20 9.61% 36.50 36.50 37.00 38.50 33.40 33.40 290,988 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.9 -2.0 - 83

C4X Discovery Holdings PLC Board Change

19/11/2021 7:00am

UK Regulatory (RNS & others)


C4x Discovery (LSE:C4XD)
Historical Stock Chart


From Oct 2021 to Jan 2022

Click Here for more C4x Discovery Charts.

TIDMC4XD

RNS Number : 8990S

C4X Discovery Holdings PLC

19 November 2021

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Board Change

19 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that Craig Fox, Chief Scientific Officer ("CSO"), has informed the Company of his intention to step down from his role and the Board, after six years of service, to pursue a new opportunity. Craig is expected to leave the Company by 31 March 2022 and a search for a new CSO has commenced. A further announcement will be made in due course.

Clive Dix, Chief Executive Officer of C4X Discovery, commented: "Craig has been an important part of the C4XD team and his scientific know-how and expertise has contributed to a plethora of exciting scientific discoveries that have led to the signing of major outlicensing agreements. On behalf of the Board, I would like to express my sincere gratitude to Craig for his dedication and valuable contribution to the Company during his six years of service. We wish Craig continued success in all his future endeavours."

Craig Fox commented: "I have thoroughly enjoyed my time at C4XD, and it has been a privilege to work with its fantastic people and to see the Company transform through its AIM-listing and subsequent multiple partnering deals. I believe the team's world-class scientific expertise, tenacity, and dedication, combined with proprietary cutting-edge technologies provide a truly ground-breaking capability that can efficiently deliver world-leading medicines that can meaningfully impact the lives of patients. I wish the team well as I move on to my next role and look forward to hearing about their next achievements."

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700 
 

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFVLLFFFLXFBV

(END) Dow Jones Newswires

November 19, 2021 02:00 ET (07:00 GMT)

1 Year C4x Discovery Chart

1 Year C4x Discovery Chart

1 Month C4x Discovery Chart

1 Month C4x Discovery Chart
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220128 20:17:22